Literature DB >> 11536182

Biased activation of human T lymphocytes due to low extracellular pH is antagonized by B7/CD28 costimulation.

M Bosticardo1, S Ariotti, G Losana, P Bernabei, G Forni, F Novelli.   

Abstract

As T cell response to tumor-associated antigens may be impaired by the acidic microenvironment typical of solid tumors, we assessed the effect of extracellular pH (pH(e)) on the activation and proliferation of human T lymphocytes and generation of the cytotoxic response. T lymphocytes stimulated with anti-CD3 mAb or PHA at low pH(e) were unable to secrete IL-2 and IFN-gamma and their ability to progress through the cell cycle was impaired. T lymphocytes also displayed up-regulation of IFN-gammaR2 chain and CTLA-4 expression, rendering them sensitive to negative regulatory signals. Agonistic mAb against CD28, but not against CD2, completely restored cytokine production and cell cycle progression, but down-regulated IFN-gammaR2 and CTLA-4 expression. The anti-CD28mAb rescued the CTL response of allogeneic anti-tumor cultures generated at low pH(e). Following anti-CD28 mAb treatment, T cells synthesized cyclooxygenase-2 (Cox-2) protein, which is involved in the early phases of T cell activation. This rescue of T cell activation was independent of the inducible 6-phosphofructo-2-kinase (iPFK-2) pathway, which stimulates proliferation in hypoxic and acidic conditions. The restoration of proliferative and cytotoxic T cell responses by CD28-triggering provides insight into the mechanisms by which B7 enhances the T cell anti-tumor response in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11536182     DOI: 10.1002/1521-4141(200109)31:9<2829::aid-immu2829>3.0.co;2-u

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  24 in total

Review 1.  Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway.

Authors:  Valéry L Payen; Paolo E Porporato; Bjorn Baselet; Pierre Sonveaux
Journal:  Cell Mol Life Sci       Date:  2015-12-01       Impact factor: 9.261

Review 2.  Exosomal Induction of Tumor Innervation.

Authors:  Paola D Vermeer
Journal:  Cancer Res       Date:  2019-05-14       Impact factor: 12.701

Review 3.  Imaging pH and metastasis.

Authors:  Arig Ibrahim Hashim; Xiaomeng Zhang; Jonathan W Wojtkowiak; Gary V Martinez; Robert J Gillies
Journal:  NMR Biomed       Date:  2011-03-08       Impact factor: 4.044

Review 4.  Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.

Authors:  Azam Bozorgi; Maryam Bozorgi; Mozafar Khazaei
Journal:  Cell Oncol (Dordr)       Date:  2022-08-09       Impact factor: 7.051

Review 5.  Metabolic regulation of T cells in the tumor microenvironment by nutrient availability and diet.

Authors:  Steven Zhao; Ronal M Peralta; Natalia Avina-Ochoa; Greg M Delgoffe; Susan M Kaech
Journal:  Semin Immunol       Date:  2021-08-27       Impact factor: 10.671

Review 6.  Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy.

Authors:  Soumaya Kouidhi; Farhat Ben Ayed; Amel Benammar Elgaaied
Journal:  Front Immunol       Date:  2018-02-23       Impact factor: 7.561

Review 7.  Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy.

Authors:  Yiliang Li; Sapna Pradyuman Patel; Jason Roszik; Yong Qin
Journal:  Front Immunol       Date:  2018-07-16       Impact factor: 7.561

Review 8.  Unravelling the Interplay between Extracellular Acidosis and Immune Cells.

Authors:  Fernando Erra Díaz; Ezequiel Dantas; Jorge Geffner
Journal:  Mediators Inflamm       Date:  2018-12-30       Impact factor: 4.711

Review 9.  Ion Channels, Transporters, and Sensors Interact with the Acidic Tumor Microenvironment to Modify Cancer Progression.

Authors:  Ebbe Boedtkjer
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 5.545

Review 10.  The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy.

Authors:  Bonnie L Russell; Selisha A Sooklal; Sibusiso T Malindisa; Lembelani Jonathan Daka; Monde Ntwasa
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.